Latest Strategic Collaborations News

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

InteliCare has secured its largest contract yet, signing a five-year $8.8 million agreement with Victorian aged care provider mecwacare to deploy its AI-driven platform across 22 residential facilities.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Classic Minerals has teamed up with Bain Global Resources to explore expanding its Goldbridge Processing Facility into a regional hub, aiming to boost gold production across Western Australia's Forrestania district.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Embark Early Education has closed its takeover bid for Mayfield Childcare, acquiring nearly 40% voting power with a strong cash acceptance rate. The move signals a significant step in sector consolidation.

Tempest Minerals has agreed to acquire a 145km² advanced gold portfolio in New Zealand’s North Island, unlocking multiple drill-ready targets in a prolific gold province. The $2 million all-scrip deal includes performance milestones tied to exploration success.

Nagambie Resources has opened a discounted Share Purchase Plan aiming to raise $3.7 million to support diamond drilling at its Whroo Mines project and bolster working capital, following a strategic joint venture announcement with Alkane Resources.

Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.